AbbVie (ABBV) Cash & Equivalents (2012 - 2026)
AbbVie (ABBV) reported Cash & Equivalents of $9.4 billion for Q1 2026, up 81.47% year-over-year from $5.2 billion in Q1 2025, and up 79.59% quarter-over-quarter from $5.2 billion in Q4 2025.
AbbVie (ABBV) Cash & Equivalents (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has 15 years of Cash & Equivalents data on file, last reported at $9.4 billion in Q1 2026.
- Cash & Equivalents for Q1 2026 came in at $9.4 billion, up 81.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.4 billion (up 81.47% YoY), and the FY2025 annual result was $5.2 billion, down 5.34% from the prior year.
- Cash & Equivalents advanced to $9.4 billion in Q1 2026 per ABBV's latest filing, from $5.2 billion in the prior quarter.
- Over five years, Cash & Equivalents peaked at $18.1 billion in Q1 2024 and troughed at $5.2 billion in Q1 2025.
- A 5-year average of $9.0 billion and a median of $8.5 billion in 2022 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2024 and 2025: Cash & Equivalents jumped 169.21% in 2024, then sank 71.36% in 2025.
- A 5-year view of Cash & Equivalents shows it stood at $9.2 billion in 2022, then surged by 39.27% to $12.8 billion in 2023, then sank by 56.89% to $5.5 billion in 2024, then decreased by 5.34% to $5.2 billion in 2025, then soared by 79.59% to $9.4 billion in 2026.
- Business Quant data shows ABBV's Cash & Equivalents at $9.4 billion in Q1 2026, $5.2 billion in Q4 2025, and $5.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 4.64 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 5.28 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 21.69 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 9.39 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 5.33 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 7.63 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 1.70 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 9.57 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.39 Bn |
| Dec 31, 2025 | 5.23 Bn |
| Sep 30, 2025 | 5.63 Bn |
| Jun 30, 2025 | 6.47 Bn |
| Mar 31, 2025 | 5.18 Bn |
| Dec 31, 2024 | 5.52 Bn |
| Sep 30, 2024 | 7.26 Bn |
| Jun 30, 2024 | 13.13 Bn |
| Mar 31, 2024 | 18.07 Bn |
| Dec 31, 2023 | 12.81 Bn |
| Sep 30, 2023 | 13.29 Bn |
| Jun 30, 2023 | 8.76 Bn |
| Mar 31, 2023 | 6.71 Bn |
| Dec 31, 2022 | 9.20 Bn |
| Sep 30, 2022 | 11.83 Bn |
| Jun 30, 2022 | 8.52 Bn |
| Mar 31, 2022 | 6.10 Bn |
| Dec 31, 2021 | 9.75 Bn |
| Sep 30, 2021 | 12.18 Bn |
| Jun 30, 2021 | 8.55 Bn |